Search results
12 lip 2024 · This guidance document provides recommendations to clinicians for treatment of infections caused by extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and difficult-to-treat Pseudomonas aeruginosa (DTR-P. aeruginosa).
- Infection Prevention & Control
IDSA/SHEA: Primer on Healthcare Epidemiology, Infection...
- Guideline Development Process
Because of the large number of clinical practice guidelines...
- Ebola
What is Ebola? Ebola virus disease is a severe illness that...
- Evaluation and Management Services
Dr. Timothy Sullivan, Vice Chair of IDSA’s Coding & Payment...
- Bio-Preparedness Workforce Pilot
On Thursday, June 15, in Washington, D.C., Axios health care...
- Lyme Disease
IDSA engages in advocacy efforts that support better Lyme...
- ID Match
The IDSA ID Match Resolution provides guiding principles for...
- Hepatitis C
Viral hepatitis is a silent epidemic. According to the...
- Infection Prevention & Control
19 kwi 2022 · A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections reviewed, updated, and expanded previously developed questions and recommendations about the treatment of ESBL-E, CRE, and DTR-P. aeruginosa infections. Because of differences in the epidemiology of resistance and availability of specific ...
25 sie 2022 · The initial guidance document on infections caused by extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa) was published on 17 September 2020.
18 lip 2023 · Guidance is presented in the form of answers to a series of clinical questions for each pathogen. Although brief descriptions of notable clinical trials, resistance mechanisms, and antimicrobial susceptibility testing (AST) methods are included, the document does not provide a comprehensive review of these topics.
27 paź 2020 · This guidance document provides recommendations for the treatment of infections caused by extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa).
18 kwi 2022 · Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
Carriage of extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) has been increasing over the last decades, especially in the community setting. This successful spread of ESBL-E might be partially explained by the fact that some plasmids with ESBL encoding genes are specifically well adapted to Enterobacterales species [1].
